Parexel and Partex Enter AI Alliance
The collaboration between Parexel and Partex is designed to leverage artificial intelligence-powered solutions to accelerate drug discovery and development.
Parexel, a clinical research organization (CRO), and Partex, a biopharmaceutical company that has developed a digital pharma platform, announced a preferred strategic alliance on Aug. 15, 2023. According to a company press release, the goal of the alliance is to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development. According to a company press release, Parexel’s experience in Phase I to IV clinical development and Partex’s big data and AI capabilities are expected to complement one another in this endeavor.
Under the agreement, clinical trial execution through Partex will be managed by Parexel as the company’s preferred CRO partner. The parties will collaborate on improving clinical trial execution through the Partex-validated AI platform, which is designed to add to and expand Parexel’s existing AI tools and capabilities. According to the release, the companies ultimately hope to further advance drug developers’ ability to understand the probability of clinical success of assets within their portfolio, as well as recommend other disease indications for which their assets may be clinically viable.
"One of the biggest and most complex challenges in drug development is anticipating the investigational therapies that will be safe and effective treatment options,” said Jamie Macdonald, CEO, Parexel, in the release. “Our innovative alliance with Partex helps to address this challenge by bringing to the forefront those assets with the strongest probability of clinical success, in turn enabling customers to focus their time and resources where it is most beneficial to patients.”
"By combining Partex's … AI capabilities with Parexel's renowned clinical research expertise, we aim to accelerate the delivery of safe and effective therapies to patients worldwide, ultimately transforming the biopharmaceutical landscape,” said Gunjan Bhardwaj, CEO, Partex, in the release. “We eagerly anticipate the unveiling of new value-generating approaches and groundbreaking innovations resulting from this collaboration.”
Source: Parexel
